DRAP Grants Permission To Another Chinese Firm To Conduct Clinical Trials Of COVID Vaccine
The Drug Regulatory Authority of Pakistan (DRAP) has granted permission to a Chinese company for third phase clinical trials of its Covid-19 vaccine in the country, local media reported on Sunday.
By Fahad Zulfikar
The clinical trials committee of the Drug Regulatory Authority of Pakistan (DRAP) has granted permission to China’s Anhui Zhifei longcom for clinical trials of its vaccine. The approval has been granted after China’s bio-pharmaceutical company, Anhui Zhifei sought permission for clinical trials in Pakistan in December 2020.
The Chinese pharma company initially, will conduct third phase clinical trial of its Covid-19 vaccine candidate in Karachi and Lahore.
Anhui Zhifei longcom will conduct its vaccine’s clinical trials in Karachi at a private hospital, while in Lahore at the University of Health Sciences and another private health facility.
At least 9,000 volunteers will participate in clinical trial of the Anhui Zhifei vaccine across the country.
Anhui Zhifei had prepared its Covid vaccine in May 2020 under the aegis of the Chinese Company of Sciences. The company had conducted the phase I and phase II trials in June 2020, in which the vaccine was found safe and effective against the disease.
Around 29,000 volunteers are participating in third phase of the clinical trial of the vaccine in different countries. After Can Sino Bio, Anhui Zhifei has been second Chinese company holding trials of its vaccine in Pakistan.
Originally published at Business recorder